1. Noninvasive Measurement of mTORC1 Signaling with 89Zr-Transferrin
   Charles Truillet et al, 2017, Clinical Cancer Research CrossRef
2. Long non-coding RNA GAS5 regulates apoptosis in prostate cancer cell lines
   M.R. Pickard et al, 2013, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease CrossRef
3. Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation
   Yu Wang et al, 2014, Molecular Cancer Therapeutics CrossRef
4. Synergistic co‐targeting of prostate‐specific membrane antigen and androgen receptor in prostate cancer
   Jose D. Murga et al, 2015, The Prostate CrossRef
5. Lemur Tyrosine Kinase 2, a novel target in prostate cancer therapy
   Kalpit Shah et al, 2015, Oncotarget CrossRef
6. Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC)
   Hielke J. Meulenbeld et al, 2013, Cancer Chemotherapy and Pharmacology CrossRef
7. A phase 2 clinical trial of everolimus plus bicalutamide for castration‐resistant prostate cancer
   Helen Chow et al, 2016, Cancer CrossRef
8. A Systematic Comparison of Antiandrogens Identifies Androgen Receptor Protein Stability as an Indicator for Treatment Response
   Tiziana Siciliano et al, 2021, Life CrossRef
9. Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review)
   PAUL TOREN et al, 2014, International Journal of Oncology CrossRef
10. Adaptations to chronic rapamycin in mice
    Sherry G. Dodds et al, 2016, Pathobiology of Aging & Age-related Diseases CrossRef
11. Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer ProgressionIn Vivo
    Christian Thomas et al, 2013, Molecular Cancer Therapeutics CrossRef
12. Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer
    Mateusz Wylaź et al, 2023, Biomedicine & Pharmacotherapy CrossRef
13. PTEN Expression in Prostate Cancer: Relationship With Clinicopathologic Features and Multiparametric MRI Findings
    Marta D. Switlyk et al, 2019, American Journal of Roentgenology CrossRef
14. Network analysis of an in vitro model of androgen-resistance in prostate cancer
    Sujitra Detchokul et al, 2015, BMC Cancer CrossRef
15. Diagnostic Value of68Ga-PSMA PET/CT for Detection of Phosphatase and Tensin Homolog Expression in Prostate Cancer: A Pilot Study
    BaoJun Wang et al, 2020, Journal of Nuclear Medicine CrossRef
16. Mechanisms of resistance to mTOR inhibitors
    Luigi Formisano et al, 2020, Critical Reviews in Oncology/Hematology CrossRef
17. Genomic Deletion at 10q23 in Prostate Cancer: More Than PTEN Loss?
    Raghavendra Tejo Karthik Poluri et al, 2018, Frontiers in Oncology CrossRef
18. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer
    L S D'Abronzo et al, 2017, Oncogene CrossRef
19. Current Phase II clinical data for ridaforolimus in cancer
    Anna Spreafico et al, 2013, Expert Opinion on Investigational Drugs CrossRef
20. Combinatorial Effect of Abiraterone Acetate and NVP-BEZ235 on Prostate Tumor Progression in Rats
    Bianca Facchim Gonçalves et al, 2018, Hormones and Cancer CrossRef
21. Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors
    Weisheng Zhang et al, 2012, Translational Oncology CrossRef
22. Evidence for Molecular Differences in Prostate Cancer between African American and Caucasian Men
    Francesca Khani et al, 2014, Clinical Cancer Research CrossRef
23. Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer
    Nair Lopes et al, 2021, Biomedicines CrossRef
24. Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention
    Nazanin Momeni Roudsari et al, 2021, Pharmaceutics CrossRef
25. Highly Conserved Homotrimer Cavity Formed by the SARS-CoV-2 Spike Glycoprotein: A Novel Binding Site
    Umesh Kalathiya et al, 2020, Journal of Clinical Medicine CrossRef